ORCID
- Jarvis, Michael: 0000-0002-0124-4061
Abstract
Lassa fever causes an approximate 5000 to 10,000 deaths annually in West Africa and cases have been imported into Europe and the Americas, challenging public health. Although Lassa virus was first described over 5 decades ago in 1969, no treatments or vaccines have been approved to treat or prevent infection. In this review, we discuss current therapeutics in the development pipeline for the treatment of Lassa fever, focusing on those that have been evaluated in humans or animal models. Several treatments, including the antiviral favipiravir and a human monoclonal antibody cocktail, have shown efficacy in preclinical rodent and non-human primate animal models and have potential for use in clinical settings. Movement of the promising preclinical treatment options for Lassa fever into clinical trials is critical to continue addressing this neglected tropical disease.
DOI
10.3390/microorganisms9040772
Publication Date
2021-04-07
Publication Title
Microorganisms
Volume
9
Issue
4
Embargo Period
2021-08-13
Organisational Unit
School of Biomedical Sciences
First Page
772
Last Page
772
Recommended Citation
Hansen, F., Jarvis, M., Feldmann, H., & Rosenke, K. (2021) 'Lassa Virus Treatment Options', Microorganisms, 9(4), pp. 772-772. Available at: https://doi.org/10.3390/microorganisms9040772
